Subscribe to this RSS feed

Newsletter

Clinuvel's regular newsletter, Clinuvel Communiqué, including archives.

Clinuvel Newsletter - February 2013

21 Feb 2013
| CEO's Outlook | US vitiligo program: treatment results published |

Clinuvel Newsletter - July 2012

03 Jul 2012

Clinuvel Newsletter - April 2012

03 Apr 2012

Clinuvel Newsletter - February 2012

29 Feb 2012

Clinuvel Newsletter - October 2011

14 Oct 2011
| CEO’s Outlook | Dossier preparation for SCENESSE® | INSPIRE vitiligo program update | Media coverage | Share price & financials | Summary of the SCENESSE® pipeline

Clinuvel Newsletter - May 2011

25 May 2011
| CEO’s Overview | Confirmatory EPP studies complete in the US & Europe | INSPIRE vitiligo program update | Guest bloggers and new video releases | Share price and financials

Clinuvel Newsletter - January 2011

10 Jan 2011
| CEO’s Outlook | ASCEM III (Luzern 23-24 January 2011) | Share consolidation – CUV/CLVLY | CUV holders: are your details up to date? | Share price and financials | Expected clinical results timeline 2011

Clinuvel Newsletter - November 2010

22 Nov 2010
| CEO’s Outlook | New research into photosensitive diseases and quality of life | Clinuvel’s new program: nonsegmental vitiligo | Share price and financials | 2010 Annual General Meeting

Clinuvel Newsletter - August 2010

23 Aug 2010
| CEO’s Outlook | US patent grant for UV protection | SCENESSE® unveiled as approved drug name | Share price and financials | A world first: SCENESSE® now available by prescription to Italian EPP patients | Clinuvel’s global clinical program

Clinuvel Newsletter - May 2010

07 May 2010
| CEO’s Outlook | US porphyria awareness week | Clinical and regulatory timeline | Life with EPP: guest blogger series | Share price and financials | European update: Clinuvel’s regulatory program focus - EPP | Clinuvel New Media Site
Page 1 of 3

Investors' Blog Posts

Q&A: SCENESSE® successful in Phase IIa vitiligo...

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

Clinuvel Director recognised in the Women of Influen...

Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...

Read More

Inside Clinuvel: Vitiligo and treatment frustrations...

Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...

Read More

Related Webcasts

What can vitiligo patients do? – Lee Thomas and Dr ...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

The future of vitiligo treatment – Lee Thomas and D...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Vitiligo trials of SCENESSE® – Lee Thomas and Dr Ph...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Investor Spotlight

Annual Report for the year ended 30 June 2012

Clinuvel's Annual Report for the year ended 30 June 2012....

Read more